Sector News

Takeda sets bidding deadline for chemical firm stake

July 26, 2016
Life sciences

Takeda Pharmaceutical Co Ltd will accept initial bids for its 70 percent stake in a chemicals company through Aug. 16, with potential suitors including CVC Capital Partners Ltd and Carlyle Group Ltd, sources told Reuters.

Takeda, Japan’s largest drugmaker by market value, aims to sell its holding in Wako Pure Chemicals Industries Ltd to streamline operations, four people familiar with the plan said, declining to be identified as the matter was private.

The winning bidder would likely buy out the remaining shareholders, taking the deal over 100 billion yen ($957.95 million), the people said.

The drugmaker is likely to receive an aggressive bid from Fujifilm Holdings Corp, which is seeking to expand its medical business and already owns 9.5 percent of Wako Pure, the people said.

Buyout firm Permira is also among companies set to bid, they said.

Takeda, Carlyle, CVC, Fujifilm and Permira declined to comment.

Takeda has invited a number of the global buyout firms to the bid for its stake in the Osaka-based maker of laboratory chemicals and clinical diagnostic reagents, which had sales of 75.7 billion yen last year, the people said.

A deal would follow the December sale of Takeda’s portfolio of respiratory drugs to Britain’s AstraZeneca PLC for $575 million. ($1 = 104.3900 yen)

By Junko Fujita

Source: Reuters

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.